EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy

Study limitation reported by the research below: “The guidance explicitly advises against using either agent as MASH-targeted therapy in cirrhosis, but safety data in that population remain limited.”